Determining a low disease activity threshold for decision to maintain disease-modifying antirheumatic drug treatment unchanged in rheumatoid arthritis patients

[1]  M. Weisman,et al.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010 , 2011, Annals of the rheumatic diseases.

[2]  F. Guillemin,et al.  Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences. , 2009, Arthritis and rheumatism.

[3]  T. Pincus,et al.  Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. , 2008, Arthritis and rheumatism.

[4]  D. Furst,et al.  Evaluating the adequacy of disease control in patients with rheumatoid arthritis: a RAND appropriateness panel. , 2007, Rheumatology.

[5]  M. Weisman,et al.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 , 2007, Annals of the rheumatic diseases.

[6]  T. Pincus,et al.  A proposed continuous quality improvement approach to assessment and management of patients with rheumatoid arthritis without formal joint counts, based on quantitative routine assessment of patient index data (RAPID) scores on a multidimensional health assessment questionnaire (MDHAQ). , 2007, Best practice & research. Clinical rheumatology.

[7]  J. Smolen,et al.  Remission by composite scores in rheumatoid arthritis: are ankles and feet important? , 2007, Arthritis research & therapy.

[8]  J. Jacobs,et al.  Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial) , 2007, Annals of the rheumatic diseases.

[9]  C. Bombardier,et al.  Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders. , 2007, The Journal of rheumatology.

[10]  H. Paulus,et al.  Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort. , 2007, Arthritis and rheumatism.

[11]  B Combe,et al.  EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) , 2006, Annals of the rheumatic diseases.

[12]  F. Guillemin,et al.  Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6 months' first-line DMARD therapy. , 2007, Joint, bone, spine : revue du rhumatisme.

[13]  P. Tugwell,et al.  Low disease activity state in rheumatoid arthritis: concepts and derivation of minimal disease activity. , 2006, Clinical and experimental rheumatology.

[14]  A Kavanaugh,et al.  Complexities in defining remission in rheumatic diseases. , 2006, Clinical and experimental rheumatology.

[15]  J. Smolen,et al.  Remission of rheumatoid arthritis: should we care about definitions? , 2006, Clinical and experimental rheumatology.

[16]  F Guillemin,et al.  Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology , 2005, Annals of the rheumatic diseases.

[17]  Philippe Ravaud,et al.  Minimal clinically important difference, low disease activity state, and patient acceptable symptom state: methodological issues. , 2005, The Journal of rheumatology.

[18]  David T Felson,et al.  Minimal disease activity for rheumatoid arthritis: a preliminary definition. , 2005, The Journal of rheumatology.

[19]  H. Mäkinen,et al.  Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? , 2005, Annals of the rheumatic diseases.

[20]  P. V. van Riel,et al.  Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial , 2005, Annals of the rheumatic diseases.

[21]  P. V. van Riel,et al.  Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. , 2004, Rheumatology.

[22]  A. McMahon,et al.  Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial , 2004, The Lancet.

[23]  van der Heijde Dm,et al.  Development of a disease activity score based on judgment in clinical practice by rheumatologists. , 1993 .

[24]  M. A. van 't Hof,et al.  Development of a disease activity score based on judgment in clinical practice by rheumatologists. , 1993, The Journal of rheumatology.

[25]  D. Mitchell,et al.  Preliminary criteria for clinical remission in rheumatoid arthritis. , 1981, Arthritis and rheumatism.

[26]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.